Comparative Pharmacology
Head-to-head clinical analysis: KALLIGA versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALLIGA versus XYZAL.
KALLIGA vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine